Compound class:
Synthetic organic
Comment: XL01126 is a VHL-based PROTAC degrader targeting leucine rich repeat kinase 2 (LRRK2). The LRRK2 binding moeity of the compound is the brain-penetrant kinase inhibitor HG-10-102-01. XL01126 is orally bioavailable and retains the ability of the parent kinase inhibitor to cross the blood-brain barrier. LRRK2 is an active therapeutic target for Parkinson's disease, since activating coding mutations in LRRK2 are associated with dominantly inherited Parkinson's disease [1-2,5]. XL01126's development was led by Dundee University's Centre for Targeted Protein Degradation and the Research Institute for Medicines at the University of Lisbon. Initially disclosed in a ChemRxiv preprint [4].
Cereblon-targeting LRRK2 PROTACs have been disclosed previously, but these were found to be inefficient target degraders [3]. |
|
Bioactivity Comments |
XL01126 blocks phosphorylation of downstream substrates (e.g. Rab10; EC50 15 nM) more effectively than the parent kinase inhibitor HG-10-102-01 (EC50 110 nM) [4]. It binds to VHL with a Ki of 2.33 μM and its DC50 for WT KRRK2 is 32 nM (Dmax 82% at 4 hrs), and for LRRK2G2019S it is 14 nM (Dmax 92% at 4 hrs). |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|